126 related articles for article (PubMed ID: 2954602)
1. Identification and quantitation of alcophosphamide, a metabolite of cyclophosphamide, in the rat using chemical ionization mass spectrometry.
Hong PS; Chan KK
Biomed Environ Mass Spectrom; 1987 Apr; 14(4):167-72. PubMed ID: 2954602
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat.
Hong PS; Srigritsanapol A; Chan KK
Drug Metab Dispos; 1991; 19(1):1-7. PubMed ID: 1673381
[TBL] [Abstract][Full Text] [Related]
3. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.
Jardine I; Fenselau C; Appler M; Kan MN; Brundrett RB; Colvin M
Cancer Res; 1978 Feb; 38(2):408-15. PubMed ID: 620410
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in the rat.
Lu H; Chan KK
Cancer Chemother Pharmacol; 2006 Oct; 58(4):532-9. PubMed ID: 16470409
[TBL] [Abstract][Full Text] [Related]
5. Half-life of oxazaphosphorines in biological fluids.
Sladek NE; Powers JF; Grage GM
Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
[TBL] [Abstract][Full Text] [Related]
6. The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry.
Momerency G; Van Cauwenberghe K; Slee PH; Van Oosterom AT; De Bruijn EA
Biol Mass Spectrom; 1994 Mar; 23(3):149-58. PubMed ID: 8148406
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508.
Chan KK; Hong PS; Tutsch K; Trump DL
Cancer Res; 1994 Dec; 54(24):6421-9. PubMed ID: 7987837
[TBL] [Abstract][Full Text] [Related]
8. Review of the metabolism and mode of action of cyclophosphamide.
Fenselau C
J Assoc Off Anal Chem; 1976 Sep; 59(5):1028-36. PubMed ID: 965325
[TBL] [Abstract][Full Text] [Related]
9. Approaches to the pharmacokinetics of cyclophosphamide (NSC 26271): Quantitation of metabolites.
Jardine I; Brundrett R; Colvin M; Fenselau C
Cancer Treat Rep; 1976 Apr; 60(4):403-8. PubMed ID: 1277214
[TBL] [Abstract][Full Text] [Related]
10. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.
Sladek NE; Doeden D; Powers JF; Krivit W
Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951
[TBL] [Abstract][Full Text] [Related]
11. Blood levels of alkylating metabolites of cyclophosphamide in the mouse after iv or oral administration.
Struck RF; Alberts DS
Cancer Treat Rep; 1984 May; 68(5):765-70. PubMed ID: 6722832
[TBL] [Abstract][Full Text] [Related]
12. Identification of new metabolites of phosphoramide and nor-nitrogen mustards and cyclophosphamide in rat urine using ion cluster techniques.
Chan KK; Hong SC; Watson E; Deng SK
Biomed Environ Mass Spectrom; 1986 Mar; 13(3):145-54. PubMed ID: 2938656
[TBL] [Abstract][Full Text] [Related]
13. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.
Struck RF; Kirk MC; Witt MH; Laster WR
Biomed Mass Spectrom; 1975 Feb; 2(1):46-52. PubMed ID: 1131393
[TBL] [Abstract][Full Text] [Related]
14. Enzymatic detoxification of phosphoramide mustard by soluble fractions from rat organ tissues.
Hong PS; Chan KK
Drug Metab Dispos; 1991; 19(3):568-73. PubMed ID: 1680621
[TBL] [Abstract][Full Text] [Related]
15. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
[TBL] [Abstract][Full Text] [Related]
16. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans.
Fenselau C; Kan MN; Rao SS; Myles A; Friedman OM; Colvin M
Cancer Res; 1977 Aug; 37(8 Pt 1):2538-43. PubMed ID: 872080
[TBL] [Abstract][Full Text] [Related]
17. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice.
Hemminki K
Cancer Res; 1985 Sep; 45(9):4237-43. PubMed ID: 4028012
[TBL] [Abstract][Full Text] [Related]
18. Characterization of cyclophosphamide (NSC-26271) metabolites and related derivatives by field-desorption and electron-impact mass spectrometry.
Przybylski M; Ringsdorf H; Voelcker G; Draeger U; Peter G; Hohorst HJ
Cancer Treat Rep; 1976 Apr; 60(4):509-16. PubMed ID: 1277228
[TBL] [Abstract][Full Text] [Related]
19. PLasma half-life and urinary excretion of cyclophosphamide in children.
Sladek NE; Priest J; Doeden D; Mirocha CJ; Pathre S; Krivit W
Cancer Treat Rep; 1980; 64(10-11):1061-6. PubMed ID: 7459891
[TBL] [Abstract][Full Text] [Related]
20. Influence of diuretics on urinary general base catalytic activity and cyclophosphamide-induced bladder toxicity.
Sladek NE; Smith PC; Bratt PM; Low JE; Powers JF; Borch RF; Coveney JR
Cancer Treat Rep; 1982 Nov; 66(11):1889-1900. PubMed ID: 7139634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
